Body Systems

Multiple Myeloma15 Results found

Studies recruiting participants:

Lymphoid Cancers Families Study

Lymphocyte cancers are the fourth most common cancer in both men and women.  Research into the genetics and environmental factors contributing to lymphoid cancers is an important step to prevent and/or control these cancers.  Multiple diagnoses of lymphoid cancer within the same family may indica

Recruiting
Principal Investigator 
Angela Brooks-Wilson
Area 
Vancouver

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)…

This study will include two parts; dose exploration (DE) and cohort expansion (CE). In the DE phase, the safety and tolerability profile of GSK'916 (belantamab mafodotin) will be evaluated when administered in combination with other anti-cancer agents.

Recruiting
Principal Investigator 
Kevin Song
Body Locations and Systems 
Blood
Area 
Vancouver
Age 
18 and above

Closed for recruitment:

A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients…

The purpose of this phase 3, randomized, double-blind, multicenter study is to compare Oral Ixazomib (MLN9708) plus Lenalidomide and Dexamethasone versus Placebo plus Lenalidomide and Dexamethasone in adult patients with relapsed and/or refractory multiple myeloma.

Closed for Recruitment
Principal Investigator 
Kevin Song
Body Locations and Systems 
Blood
Area 
Vancouver
Age 
18 and above

A Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly…

The purpose of the study is to compare once-weekly carfilzomib dosing in combination with dexamethasone to twice-weekly carfilzomib dosing in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma, previously treated with bortezomib and an immunomodulatory agent

Closed for Recruitment
Principal Investigator 
Kevin Song
Body Locations and Systems 
Blood
Area 
Vancouver
Age 
18 and above

An Investigational Immuno-therapy Study of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma (CheckMate 602)

The purpose of this study is to evaluate the safety and effectiveness of several combination therapies for Multiple Myeloma. Upon entry into the study, patients will be randomized (assigned by chance) to receive either:

Closed for Recruitment
Principal Investigator 
Kevin Song
Body Locations and Systems 
Blood, Heart and Circulation
Area 
Vancouver
Age 
18 and above

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON

This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study will compare the efficacy and health-related quality of life (HR-QoL) and assess the safety of selinexor plus bortezomib (Velcade® or generic equivalent) plus low-dose dexamethasone (SVd) versus bortezomi

Closed for Recruitment
Principal Investigator 
Heather J. Sutherland
Body Locations and Systems 
Blood
Area 
Vancouver
Age 
18 years and above

Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or…

This trial will evaluate the efficacy and safety of combination of pomalidomide (POM) and low-dose dexamethasone (LD-Dex) (Cohort A) or the combination of pomalidomide (POM) , daratumumab (DARA) and low-dose dexamethasone (LD-Dex) (Cohort B) in subjects with relapsed or refractory multiple myelom

Closed for Recruitment
Principal Investigator 
Kevin Song
Body Locations and Systems 
Blood
Area 
Vancouver
Age 
18 and above

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

The purpose of this study is to compare the effectiveness of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple myeloma.

Closed for Recruitment
Principal Investigator 
Heather J. Sutherland
Body Locations and Systems 
Blood
Area 
Vancouver
Age 
18 and above